Format

Send to

Choose Destination
Clin Colorectal Cancer. 2018 Oct 16. pii: S1533-0028(18)30300-1. doi: 10.1016/j.clcc.2018.10.001. [Epub ahead of print]

Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

Author information

1
Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway. Electronic address: marianne.gronlie.guren@ous-hf.no.
2
Department of Registration, Cancer Registry of Norway, Oslo, Norway.
3
Department of Research, Cancer Registry of Norway, Oslo, Norway.
4
Department of Oncology, Haukeland University Hospital and Institute of Clinical Science, Medical Faculty, University of Bergen, Bergen, Norway.

Abstract

BACKGROUND:

Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC.

MATERIALS AND METHODS:

All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival.

RESULTS:

Median age was 66 years; 71% were females. World age-standardized incidence rates increased (1987-2016) from 0.79 (95% confidence interval [CI], 0.69-0.90) to 1.10 (95% CI, 1.00-1.22) per 100,000 person-years in females and, from 0.34 (95% CI, 0.28-0.42) to 0.47 (95% CI, 0.40-0.54) in males. Estimated annual percentage change was 1.7 (95% CI, 0.9-2.6) for females and 1.3 (95% CI, -0.1 to 2.7) for males. Incidence rates increased with age; the relative risk was higher in major cities. Five-year net survival increased from 63.4% to 72.7% (1987-2016), but for age ≥ 70 years remained ∼57%. Net survival was dependant on stage, age, and gender. Five-year net survival (1997-2016) was 76.4% after curative radiotherapy, and 18.0% after palliative radiotherapy.

CONCLUSION:

ASCC incidence rates increased from 1987 to 2016, and survival improved for patients < 70 years. Five-year net survival was 76% after curative radiotherapy in Norway.

KEYWORDS:

Anal cancer; Cancer registry; Epidemiology; Human papilloma virus; Radiotherapy

PMID:
30415990
DOI:
10.1016/j.clcc.2018.10.001

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center